Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$38.70 USD
-0.29 (-0.74%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $38.73 +0.03 (0.08%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
MIRM 38.70 -0.29(-0.74%)
Will MIRM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MIRM
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should First Trust Small Cap Core AlphaDEX ETF (FYX) Be on Your Investing Radar?
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?
Other News for MIRM
Interesting MIRM Put And Call Options For November 15th
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc
Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences